Innova Captab Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5k3thyxxvrr7y83kxwsesyre.pdf

Key Takeaways


Jammu Expansion: The Growth Engine

Lohariwala: "With the help of Jammu plant, we are feeling that again we will double our revenue and bottom-line numbers to double in the next 3 years."

CDMO Business & Schedule M Opportunity

Lohariwala: "We see it as a great opportunity in the CDMO space not only for the Innova for all the companies. Those who will comply with the regulation will go ahead into the curve and will attract the good business."

Capacity & Utilization


Business Segments & Mix


API Sourcing & Input Costs


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGRMaintain 35% CAGRNext 3–4 years
Jammu commercializationCephalosporin block via tech transferSeptember 2024 (Q2 FY25)
Jammu revenue contributionRevenue begins; first two quarters difficultQ3 FY25
Jammu margin improvementNoticeable from second yearFY27 onwards
Jammu revenue target₹800–₹900 crores at 40–50% utilization3–4 years
Jammu FY26 revenueBetter than ₹200–₹300 croresFY26
Revenue doublingDouble revenue and bottom-line numbersNext 3 years
Domestic branded generics CAGRMaintain 30%+Ongoing
CDMO business shareRemain at 56–58%Future
Trade generics shareMaintain 17% constituentAs company doubles in 3 years
CapexMaintenance capex at 3–4% of gross block; R&D capex ₹10–₹15 crores this yearUntil next manufacturing facility planned
Blended growth FY25Better than 12–15% (Jammu data added)FY25
MarginsRemain at similar levelOngoing

Key Metrics

MetricQ1 FY25
Total income₹296 cr, +27% YoY and +10.5% QoQ
EBITDA₹44 cr, +37% YoY and +1% QoQ
EBITDA margin15.1%, vs 13.9% in Q1 FY24 and 16.7% in Q4 FY24
PAT₹29.5 cr, +68% YoY and +3% QoQ
PAT margin10%, vs 7.5% in Q1 FY24 and 10.9% in Q4 FY24
Revenue CAGR (past 3-4 years)35%
Revenue doubling expectationDouble in next 3 years, with help of Jammu plant
CDMO share of total income57%, expected to remain 56%-58% in future
Domestic branded generics share17%
International branded generics share11%
Sharon share15%
Group capacity utilization~52%
Tablet/capsule capacity utilization~45%
Cephalosporin and original block utilization70% to 80%-85%
Jammu plant capex~₹450 cr
Jammu plant revenue potential (at 40%-50% utilization)₹800-₹900 cr in 3-4 years
Jammu plant commercialization timelineQ2 FY25, revenue from Q3 FY25
API domestic sourcing70%-80%
Branded generics sales force~300 persons
R&D capex (Panchkula)₹10-₹15 cr total expenditure this year
Maintenance capex3%-4% of gross block